MedTrace Logo

Trial Outcomes & Findings for Pembrolizumab In Central Nervous System Metastases (NCT NCT02886585)

NCT ID: NCT02886585

Last Updated: 2026-07-21

Results Overview

Contrast-enhanced cranial MRI will be performed every 6 weeks. Intracranial benefit rate is defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) by RANO (Response assessment in neuro-oncology) criteria for brain metastases. CR is defined as the complete disappearance of all disease sustained for at least 4 weeks. PR is defined as greater than or equal to 30% decrease compared to baseline in the sum of target lesions sustained for at least 4 weeks and no progression of non-measurable disease. Stable disease is defined as not qualifying for CR, PR, or disease progression. The proportion of patients in each cohort with a best response of CR or PR will be presented with a 90% confidence interval estimated using the method of Atkinson and Brown, which allows for the two-stage design.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE2

Target enrollment

101 participants

Primary outcome timeframe

44 months

Results posted on

2026-07-21

Participant Flow

Participant milestones

Participant milestones
Measure
Neoplastic Meningitis-Cohort C
* Neoplastic Meningitis * Histologically confirmed solid malignancy * Positive Cytology * Baseline Brain MRI * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Previously Untreated Brain Metastases-Cohort A
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
1-4 Brain Metastases From Melanoma Cohort D
* 1-4 Brain Metastases from Melanoma * Clinical indication for stereostatic radiosurgery * Evaluable extracranial focus * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis. * Brain MRI and PET CT Pembrolizumab MRI PET/CT Stereotactic Radiosurgery
Overall Study
STARTED
22
10
48
21
Overall Study
COMPLETED
20
9
48
19
Overall Study
NOT COMPLETED
2
1
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Neoplastic Meningitis-Cohort C
* Neoplastic Meningitis * Histologically confirmed solid malignancy * Positive Cytology * Baseline Brain MRI * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Previously Untreated Brain Metastases-Cohort A
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
1-4 Brain Metastases From Melanoma Cohort D
* 1-4 Brain Metastases from Melanoma * Clinical indication for stereostatic radiosurgery * Evaluable extracranial focus * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis. * Brain MRI and PET CT Pembrolizumab MRI PET/CT Stereotactic Radiosurgery
Overall Study
Withdrawal by Subject
1
1
0
0
Overall Study
Clinical deterioration
1
0
0
0
Overall Study
Still in follow-up per protocol (Cohort D)
0
0
0
2

Baseline Characteristics

Pembrolizumab In Central Nervous System Metastases

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Previously Untreated Brain Metastases-Cohort A
n=10 Participants
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
n=48 Participants
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Neoplastic Meningitis-Cohort C
n=22 Participants
* Neoplastic Meningitis * Histologically confirmed solid malignancy * Positive Cytology * Baseline Brain MRI * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
1-4 Brain Metastases From Melanoma Cohort D
n=21 Participants
* 1-4 Brain Metastases from Melanoma * Clinical indication for stereostatic radiosurgery * Evaluable extracranial focus * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis. * Brain MRI and PET CT Pembrolizumab MRI PET/CT Stereotactic Radiosurgery
Total
n=101 Participants
Total of all reporting groups
Age, Continuous
54.5 years
n=9 Participants
52 years
n=27 Participants
51.5 years
n=267 Participants
56 years
n=265 Participants
54 years
n=568 Participants
Sex: Female, Male
Female
7 Participants
n=9 Participants
40 Participants
n=27 Participants
21 Participants
n=267 Participants
18 Participants
n=265 Participants
86 Participants
n=568 Participants
Sex: Female, Male
Male
3 Participants
n=9 Participants
8 Participants
n=27 Participants
1 Participants
n=267 Participants
3 Participants
n=265 Participants
15 Participants
n=568 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
0 Participants
n=265 Participants
0 Participants
n=568 Participants
Race (NIH/OMB)
Asian
2 Participants
n=9 Participants
2 Participants
n=27 Participants
0 Participants
n=267 Participants
2 Participants
n=265 Participants
6 Participants
n=568 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
0 Participants
n=265 Participants
0 Participants
n=568 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=9 Participants
1 Participants
n=27 Participants
1 Participants
n=267 Participants
0 Participants
n=265 Participants
2 Participants
n=568 Participants
Race (NIH/OMB)
White
7 Participants
n=9 Participants
41 Participants
n=27 Participants
20 Participants
n=267 Participants
19 Participants
n=265 Participants
87 Participants
n=568 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants
1 Participants
n=27 Participants
0 Participants
n=267 Participants
0 Participants
n=265 Participants
1 Participants
n=568 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=9 Participants
3 Participants
n=27 Participants
1 Participants
n=267 Participants
0 Participants
n=265 Participants
5 Participants
n=568 Participants

PRIMARY outcome

Timeframe: 44 months

Contrast-enhanced cranial MRI will be performed every 6 weeks. Intracranial benefit rate is defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) by RANO (Response assessment in neuro-oncology) criteria for brain metastases. CR is defined as the complete disappearance of all disease sustained for at least 4 weeks. PR is defined as greater than or equal to 30% decrease compared to baseline in the sum of target lesions sustained for at least 4 weeks and no progression of non-measurable disease. Stable disease is defined as not qualifying for CR, PR, or disease progression. The proportion of patients in each cohort with a best response of CR or PR will be presented with a 90% confidence interval estimated using the method of Atkinson and Brown, which allows for the two-stage design.

Outcome measures

Outcome measures
Measure
Previously Untreated Brain Metastases-Cohort A
n=9 Participants
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
n=48 Participants
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Intracranial Benefit Rate (Cohorts A and B)
33.3 percentage of patients
Interval 10.0 to 65.0
43.8 percentage of patients
Interval 31.0 to 57.0

PRIMARY outcome

Timeframe: 3 Months

Overall survival at three months is defined as the proportion of patients alive three months after enrollment. Any patient whose vital status is unknown due to loss of follow-up will be classified as having died for purposes of estimating the primary endpoint. The proportion of patients alive at three months will be summarized with a 90% confidence interval estimated using the method of Atkinson and Brown, which allows for the two-stage design.

Outcome measures

Outcome measures
Measure
Previously Untreated Brain Metastases-Cohort A
n=20 Participants
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Overall Survival at Three Months (Cohort C)
0.60 proportion of patients
Interval 0.39 to 0.78
—

PRIMARY outcome

Timeframe: Data collection is ongoing for this objective. The longest time a single patient has been followed for this measure is 6 years.

The proportion of patients with a best extracranial response of CR or PR will be presented with a 90% confidence interval estimated using the method of Atkinson and Brown, which allows for the two-stage design.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 44 months

Toxicities were assessed per the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 54 months

Overall Survival (OS) is defined as the time from registration until death due to any cause, or censored at last date known alive.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 16 months

Intracranial response rate is defined as the percentage of patients who achieved a complete response (CR) or partial response (PR) by RANO (Response assessment in neuro-oncology) criteria for brain metastases. CR is defined as the complete disappearance of all disease sustained for at least 4 weeks. PR is defined as greater than or equal to 30% decrease compared to baseline in the sum of target lesions sustained for at least 4 weeks and no progression of non-measurable disease.

Outcome measures

Outcome measures
Measure
Previously Untreated Brain Metastases-Cohort A
n=20 Participants
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Intracranial Response Rate (Cohort C)
0 Participants
—

SECONDARY outcome

Timeframe: 44 months

Population: Cohorts A and B are analyzed together per the statistical considerations section of the protocol. 17 patients in this group did not have measurable extracranial disease at the time of enrollment, so the remaining 40 patients were analyzed.

Extracranial response is defined as a complete response (CR, disappearance of all target lesions) or partial response (PR, 30% or greater decrease in the sum of diameters of target lesions in comparison with baseline) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1.

Outcome measures

Outcome measures
Measure
Previously Untreated Brain Metastases-Cohort A
n=40 Participants
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
n=20 Participants
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Extracranial Response Rate (Cohorts A and B Combined, C)
7.5 percentage of participants
Interval 2.0 to 18.0
0 percentage of participants
No patients achieved a CR or PR in cohort C.

SECONDARY outcome

Timeframe: Up to 44 months

Progression free survival (PFS) is defined as the time from registration to the earlier of disease progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 44 months

Progression free survival (PFS) is defined as the time from registration to the earlier of disease progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

Outcome measures

Outcome data not reported

Adverse Events

Previously Untreated Brain Metastases-Cohort A

Serious events: 6 serious events
Other events: 9 other events
Deaths: 10 deaths

Progressive Brain Metastases-Cohort B

Serious events: 31 serious events
Other events: 48 other events
Deaths: 43 deaths

Neoplastic Meningitis-Cohort C

Serious events: 16 serious events
Other events: 20 other events
Deaths: 20 deaths

1-4 Brain Metastases From Melanoma Cohort D

Serious events: 11 serious events
Other events: 21 other events
Deaths: 17 deaths

Serious adverse events

Serious adverse events
Measure
Previously Untreated Brain Metastases-Cohort A
n=10 participants at risk
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
n=48 participants at risk
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Neoplastic Meningitis-Cohort C
n=21 participants at risk；n=22 participants at risk
* Neoplastic Meningitis * Histologically confirmed solid malignancy * Positive Cytology * Baseline Brain MRI * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
1-4 Brain Metastases From Melanoma Cohort D
n=21 participants at risk
* 1-4 Brain Metastases from Melanoma * Clinical indication for stereostatic radiosurgery * Evaluable extracranial focus * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis. * Brain MRI and PET CT Pembrolizumab MRI PET/CT Stereotactic Radiosurgery
Gastrointestinal disorders
Abdominal distension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Abdominal pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Acidosis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Acute kidney injury
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Adrenal insufficiency
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Alanine aminotransferase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Alkaline phosphatase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Altered Mental Status
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Anorexia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Anxiety
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Ascites
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Aspartate aminotransferase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Ataxia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Back pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Blood bilirubin increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Bone pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Cerebral Edema
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Cognitive disturbance
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Colitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Colonic obstruction
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Confusion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Surgical and medical procedures
Craniotomy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Creatinine increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Death
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.1%
2/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Dehydration
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Delirium
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Depressed level of consciousness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Depression
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Diplopia, Bilateral
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Disease Progression
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dizziness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Double Vision
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysarthria
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysphasia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Dyspnea
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Expressive Aphasia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Facial muscle weakness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Failure To Thrive
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Fall
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Fatigue
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Fever
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Flank pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Gait disturbance
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Hallucinations
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Headache
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
18.2%
4/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Hearing impaired
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyperglycemia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hypertension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyponatremia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Hypophysitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hypotension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Infection -Other; Influenza B
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Intracranial hemorrhage
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Loss Of Consciousness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Lung infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Lymphocyte count decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Memory impairment
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness left-sided
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.1%
2/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness right-sided
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Nausea
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
13.6%
3/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Pain in extremity
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Pericardial effusion
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Pericarditis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Pituitary Hypophysitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Platelet count decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Receptive Aphasia/Cognitive Disturbance
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Surgical and medical procedures
Repeat Craniotomy For Tumor Resection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Sinus tachycardia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.1%
2/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - other
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Surgical and medical procedures
Right Frontal Craniotomy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Seizure
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Sepsis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Shunt Malfunction
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Somnolence
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Surgical and medical procedures
Surgical Other - Vp Shunt Placement
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Syncope
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Thromboembolic event
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Thrombus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary incontinence
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary retention
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.5%
1/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Vomiting
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.1%
2/22 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.

Other adverse events

Other adverse events
Measure
Previously Untreated Brain Metastases-Cohort A
n=10 participants at risk
\- Previously Untreated Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Progressive Brain Metastases-Cohort B
n=48 participants at risk
\- Progressive Brain Metastases * Baseline Brain MRI and PET CT * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
Neoplastic Meningitis-Cohort C
n=21 participants at risk；n=22 participants at risk
* Neoplastic Meningitis * Histologically confirmed solid malignancy * Positive Cytology * Baseline Brain MRI * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. * Brain MRI and PET/CT Pembrolizumab MRI PET/CT
1-4 Brain Metastases From Melanoma Cohort D
n=21 participants at risk
* 1-4 Brain Metastases from Melanoma * Clinical indication for stereostatic radiosurgery * Evaluable extracranial focus * For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis. * Brain MRI and PET CT Pembrolizumab MRI PET/CT Stereotactic Radiosurgery
Gastrointestinal disorders
Mouth Sore
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Mucositis oral
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Memory impairment
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Mood Swings
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle Cramps
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Pain
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
18.8%
9/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness left-sided
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Pain (Left Eye)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness right-sided
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Muscle weakness upper limb
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Myalgia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Myositis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Nasal congestion
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Nausea
40.0%
4/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
31.2%
15/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
38.1%
8/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
38.1%
8/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Neck Spasm
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Nervous System Disorders - Other, Elevated Icp
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Neutrophil count decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Neutrophilia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Night Sweats
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Non-cardiac chest pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Nose Bleeds
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Nuchal Rigidity
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Numbness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Numbness (Right Toes)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Numbness In Lower Extremities
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Numbness, Right Leg
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Ocular Migraines
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
[lle, Small, Erythematous] subcutaneous Nodules
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
[occasional] Belching
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Abdominal Cramping (Gi)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Abdominal Discomfort
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Abdominal distension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Abdominal pain
30.0%
3/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Abducens nerve disorder
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Acid Reflux
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Acidosis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Activated partial thromboplastin time prolonged
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Acute Hemiparesis, Right
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Acute kidney injury
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Adrenal insufficiency
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Agitation
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Alanine aminotransferase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
20.8%
10/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Alkaline phosphatase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Immune system disorders
Allergic reaction
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Allergies
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Alopecia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Altered Mental Status
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Anemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
22.9%
11/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Angioma
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Aniscoria
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Anorexia
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
25.0%
12/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Anxiety
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Aphasia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Arthritis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Ascites
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Aspartate aminotransferase increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
22.9%
11/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Ataxia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Auditory hallucinations
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Back pain
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
20.8%
10/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
33.3%
7/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Balance Difficulty
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Bilateral Dysmetria
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Bilateral Hand Numbness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Bilateral Lower Extremity Cramping
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Binocular Diplopia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Bleeding From Hemorrhoids
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Bloating
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Blood bilirubin increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Blurred vision
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Body Aches
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Bone pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Bradycardia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Reproductive system and breast disorders
Breast pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Brittle Nails
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Bronchial infection
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Bruise - Upper Thigh
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Bun Increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Canker Sores
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Cardiac troponin T increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
CD4 lymphocytes decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Cervical Lymphadenopathy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Chest pain - cardiac
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Chest Tightness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Chest wall pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Chills
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Chin Rash
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Cold Sores
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Colitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Concentration impairment
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Confusion
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
25.0%
12/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Conjunctivitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Constipation
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
29.2%
14/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
42.9%
9/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Coordination Difficulty
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Corneal Abrasion Os
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Cough
30.0%
3/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.6%
7/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Covid-19 Infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
CPK increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Cramping (Calves, Right Hand)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Craniotomy Site Bleeding
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Creatinine increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Death NOS
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Decreased Egfr
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Decreased Peripheral Vision
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Deep Vein Thrombosis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Dehydration
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Deja Vu
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Delirium
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Oral pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Dental Problem - Unspecified
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Depressed level of consciousness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Depression
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Dermatitis radiation
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Diaphoresis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Diarrhea
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
20.8%
10/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Diplopia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Discharge, Left Eye
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dizziness
40.0%
4/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
25.0%
12/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Dry eye
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Dry mouth
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Dry skin
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Duodenal hemorrhage
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysarthria
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysgeusia
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysmetria
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Dyspepsia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Dysphagia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Dysphasia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Dyspnea
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Dysuria
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Ear pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Eczema
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Edema cerebral
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Edema face
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Edema limbs
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Egfr Decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Electrocardiogram QT corrected interval prolonged
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Elevated D-Dimer
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Elevated Glucose
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Elevated LDH
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Elevated TSH
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Elevated WBC
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Epidydimitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Erythema, Upper Back
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Expressive Aphasia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
External ear inflammation
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Eye Infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Eye Lid Changes
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Eye pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Eye Twitch
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Eyelid Droop
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Facial Droop, Right
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Facial muscle weakness
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Facial Neuropathy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Facial Numbness With Lip Tingling
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Facial Numbness, Left Side
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Failure To Thrive
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Fall
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
25.0%
12/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Fatigue
50.0%
5/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
60.4%
29/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
38.1%
8/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Fecal incontinence
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Fever
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Flank pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Flatulence
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Floaters
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Flu like symptoms
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Fracture
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Gait disturbance
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
35.4%
17/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Gastroesophageal reflux disease
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Gastrointestinal pain
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
30.0%
3/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
20.8%
10/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Glaucoma
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Hallucinations
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Head Pressure
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Headache
30.0%
3/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
43.8%
21/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Hearing impaired
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hematoma
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Hematuria
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Hemorrhoids
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Blood and lymphatic system disorders
Hepatotoxicity
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Hiccups
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Hip Pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Immune system disorders
Hives
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Hoarseness
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hot Flashes
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Hydrocephalus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Hydronephrosis, Left
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypercalcemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyperglycemia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
38.1%
8/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyperkalemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypermagnesemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypernatremia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyperphosphatemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hypertension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Hyperthyroidism
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyperuricemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypoalbuminemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypocalcemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypoglycemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypokalemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
23.8%
5/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypomagnesemia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hyponatremia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
22.9%
11/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Hypophosphatemia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Hypotension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Hypothyroidism
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Ileus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Imbalance
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Impaired Coordination
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Inability To Close Left Eye
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Increased Thirst
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Increased Intracranial Pressure (Pressure Waves)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Increased Intraocular Pressure OD
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Increased LDH
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Indigestion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Infection Other - Pneumonia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Oral Thrush
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Ingrown Toenail
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
INR increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Psychiatric disorders
Insomnia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
16.7%
8/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Intermittent Word Finding Difficulties
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Oropharyngeal Thrush
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Intracranial hemorrhage
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Reproductive system and breast disorders
Irregular menstruation
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Itchiness, Right Eye
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Left Flank Rash
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Lacerations
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Lazy Eye (Left)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left Arm, altered Temperature
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Orthostatic Hypotension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Left DVT (Acute)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Left Eye Haziness And Folter
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left Facial Droop
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left Leg Numbness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left Pronator Drift
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Left Side Peripheral Vision Loss
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left Sided Neglect
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Left Wrist Pain (From Fall)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Left-Sided Facial Numbness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Lethargy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Lightheadedness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Surgical and medical procedures
Lithotrypsy/Stent
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Lower Left Extremity, Small, Erythematous Subcutaneous Nodules
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Localized edema
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Loose Stool
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Loss Of Proprioception
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Lymphocyte count decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Malaise
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
10.4%
5/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Pain in extremity
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
28.6%
6/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Pain of skin
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Pain, Left Side
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Pallor
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Papilledema
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Paresthesia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Paronychia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Pericardial effusion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Pericarditis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Periorbital edema
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Peripheral motor neuropathy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Peripheral sensory neuropathy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Phantosmia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Pharyngitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Photophobia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Photosensitivity
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Platelet count decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Pneumonitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Injury, poisoning and procedural complications
Poison Oak Reaction
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Polydipsia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Poor Handwriting
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Posterior Vitreous Detachment OU
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
General disorders
Post-Nasal Drip
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Musculoskeletal and connective tissue disorders
Proximal Muscle Weakness
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Pruritus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
PT Increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Ptosis
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Rash
20.0%
2/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Rash acneiform
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Rash maculo-papular
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Rectal hemorrhage
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Reduced Oral Intake
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Renal And Urinary Disorders - Other, Mild Hydronephrosis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Renal calculi
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - other
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Right 6th Nerve Palsy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Right Thyroid Nodule
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Right-Sided Orbiting
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Status Post OD trabeculectomy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Scalp pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Seizure
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
12.5%
6/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
19.0%
4/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Sinus bradycardia
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Sinus tachycardia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Sinus Thrombus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Sinusitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Skin infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Skin Rash From Flea Bites
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Skin and subcutaneous tissue disorders
Skin/Subcutaneous Disorder, Other (Left Knee)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Somnolence
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Respiratory, thoracic and mediastinal disorders
Sore throat
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Spasticity
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Stomach pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Syncope
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Tachycardia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Reproductive system and breast disorders
Testicular pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Vascular disorders
Thromboembolic event
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Thrush
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Thyroiditis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Endocrine disorders
Thyromegaly
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Tinnitus
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Tooth infection
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Toothache
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Transient Increase In Intracranial Pressure
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Transmanitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Tremor
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Upper respiratory infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urethral bleeding
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urethral calcification
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary frequency
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary Hesitancy
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary incontinence
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary retention
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.2%
2/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Infections and infestations
Urinary tract infection
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary tract pain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Renal and urinary disorders
Urinary urgency
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Urine output decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Immune system disorders
Uvulitis
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Reproductive system and breast disorders
Vaginal Cyst
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Vasovagal reaction
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Cardiac disorders
Ventricular tachycardia
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Ear and labyrinth disorders
Vertigo
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Visual Changes
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Visual Disorder - Other (R Hemianopsia)
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Visual Distortion
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Visual Disturbance
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Gastrointestinal disorders
Vomiting
40.0%
4/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
16.7%
8/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
52.4%
11/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
38.1%
8/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Watering eyes
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Weakness, Left Leg [worsening]
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Weight gain
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
8.3%
4/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Weight loss
10.0%
1/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
9.5%
2/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
White blood cell decreased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
6.2%
3/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
14.3%
3/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Nervous system disorders
Word Finding Difficulties
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Eye disorders
Worsening Vision
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Metabolism and nutrition disorders
Low TSH
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
4.8%
1/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
Investigations
Lymphocyte count increased
0.00%
0/10 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
2.1%
1/48 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.
0.00%
0/21 • All adverse events are recorded from the time of registration through 30 days after the end of study treatment. Serious adverse events are recorded through 90 days after the last dose of study treatment or the initiation of new anti-cancer therapy, whichever is sooner. Serious and non-serious adverse events were followed for a single patient for a maximum of 44 months, and all-cause mortality was followed for a maximum of 54 months.

Additional Information

Priscilla Brastianos, MD

Massachusetts General Hospital

Phone: (617) 724-4000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place